| |
Control (n=7) |
|
FS (n=7) |
|
| Age, mean (range) |
73.4 |
(57-81) |
59.3 |
(35-79) |
| T stage |
|
|
|
|
| T1 |
1 (14%) |
|
1 (14%) |
|
| T2 |
3 (43) |
|
2 (29) |
|
| T3 |
2 (29) |
|
3 (43) |
|
| T4 |
1 (14) |
|
1 (14) |
|
| N stage |
|
|
|
|
| N1 |
1 (14) |
|
1 (14) |
|
| N2 |
5 (71) |
|
4 (57) |
|
| N3 |
1 (14) |
|
2 (29) |
|
| M Stage |
|
|
|
|
| M0 |
5 (71) |
|
6 (86) |
|
| M1 |
2 (29) |
|
1 (14) |
|
| Stage (AJCC 7th edition) |
|
|
|
|
| IIIA |
3 (43) |
|
4 (57) |
|
| IIIB |
2 (29) |
|
2 (29) |
|
| IV |
2 (29) |
|
1 (14) |
|
| Location of primary tumor |
|
|
|
|
| RUL |
5 (71) |
|
4 (57) |
|
| RML |
0 |
|
1 (14) |
|
| RLL |
0 |
|
1 (14) |
|
| LUL |
1 (14) |
|
0 |
|
| LLL |
1 (14) |
|
1 (14) |
|
| Dose (cGy), median (range) |
7200 |
(7000-8000) |
7000 |
(5000-8000) |
| Histology |
|
|
|
|
| squamous cell carcinoma |
2 (29) |
|
3 (43) |
|
| adenocarcinoma |
3 (43) |
|
2 (29) |
|
| sarcomatoid carcinoma |
1 (14) |
|
1 (14) |
|
| NSCLC, other |
1 (14) |
|
1 (14) |
|
| Chemotherapy |
|
|
|
|
| Concurrent |
1 (14) |
|
3 (43) |
|
| Sequential |
5 (71) |
|
3 (43) |
|
| No chemotherapy |
1 (14) |
|
1 (14) |
|
| Chemotherapy Regimen |
|
|
|
|
| Carboplatin and docetaxol |
3 (43) |
|
2 (29) |
|
| Carboplatin and pemetrexed |
1 (14) |
|
0 |
|
| Carboplatin and gemcitabine |
1 (14) |
|
1 (14) |
|
| Cisplatin and docetaxol |
0 |
|
2 (29) |
|
| Cisplatin and pemetrexed |
1 (14) |
|
1 (14) |
|
| Pulmonary Function, mean (range) |
|
|
|
|
| FEV1 (L) |
1.365 |
(1.29-1.44) |
2.815 |
(0.88-4.07) |
| DLCO (%) |
61.5 |
(43-80) |
59.5 |
(39-97) |
| Tobacco History |
|
|
|
|
| Current smoker |
0 |
|
2 (29) |
|
| Former smoker |
6 (86) |
|
5 (71) |
|
| Pack-Years, median (range) |
45 |
(20-120) |
45 |
(3.5-100) |
| Non-smoker |
1 (14) |
|
0 |
|
|
